Invivyd (IVVD) Non Operating Income (2021 - 2025)
Invivyd posted quarterly Non Operating Income of $1.5 million for Q4 2025, up 88.93% year-on-year from $786000.0 in Q4 2024, and up 168.54% on a QoQ basis from $553000.0 in Q3 2025.
Invivyd (IVVD) has 5 years of Non Operating Income data on file, last reported at $1.5 million in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Income rose 88.93% year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2025 stood at $3.1 million (down 55.82% YoY), and the FY2025 full-year result was $3.1 million, down 55.82% from the prior year.
- Non Operating Income for Q4 2025 stood at $1.5 million, up from $553000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $3.8 million in Q1 2023 and bottomed at $9000.0 in Q1 2021.
- The 5-year median for Non Operating Income is $1.1 million (2024), against an average of $1.5 million.
- The widest annual swing landed in 2022, when Non Operating Income soared 7479.17%; it then plunged 80.0% in 2025.
- A 5-year view of Non Operating Income shows it stood at $48000.0 in 2021, then jumped by 7479.17% to $3.6 million in 2022, then fell by 14.84% to $3.1 million in 2023, then slumped by 74.63% to $786000.0 in 2024, then soared by 88.93% to $1.5 million in 2025.
- The last three Non Operating Income figures came in at $1.5 million (Q4 2025), $553000.0 (Q3 2025), and $400000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | 1.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.49 Mn |
| Sep 30, 2025 | 553,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 633,000.00 |
| Dec 31, 2024 | 786,000.00 |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Mar 31, 2024 | 2.59 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Sep 30, 2023 | 3.62 Mn |
| Jun 30, 2023 | 3.65 Mn |
| Mar 31, 2023 | 3.75 Mn |
| Dec 31, 2022 | 3.64 Mn |
| Sep 30, 2022 | 2.24 Mn |
| Jun 30, 2022 | 759,000.00 |
| Mar 31, 2022 | 73,000.00 |
| Dec 31, 2021 | 48,000.00 |
| Sep 30, 2021 | 43,000.00 |
| Jun 30, 2021 | 18,000.00 |
| Mar 31, 2021 | 9,000.00 |